

Spinal Muscular Atrophy (SMA) Therapeutics Companies And Drugs Pipeline Review 2016

PUNE, INDIA, September 12, 2016 /EINPresswire.com/ --

[Spinal Muscular Atrophy \(SMA\) - Pipeline Review, H2 2016](#)

COMPLETE REPORT DETAILS @ <https://www.wiseguyreports.com/reports/636748-spinal-muscular-atrophy-sma-pipeline-review-h2-2016>

The, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016', provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

GET A SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/636748-spinal-muscular-atrophy-sma-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA)
- The report reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Spinal Muscular Atrophy (SMA) therapeutics and enlists all their major and minor projects
- The report assesses Spinal Muscular Atrophy (SMA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents – Major Key Points

Spinal Muscular Atrophy (SMA) - Companies Involved in Therapeutics Development	21
Astellas Pharma Inc.	21
AveXis, Inc.	22
Bio Blast Pharma Ltd.	23
Cytokinetics, Inc.	24
F. Hoffmann-La Roche Ltd.	25
Genethon	26
Genzyme Corporation	27
Ionis Pharmaceuticals, Inc.	28
Neurodyn Inc.	29
Neurotune AG	30
Novartis AG	31
Paratek Pharmaceuticals, Inc.	32
RaNA Therapeutics, Inc.	33
Sarepta Therapeutics, Inc.	34
Voyager Therapeutics, Inc.	35
WAVE Life Sciences Ltd.	36
Spinal Muscular Atrophy (SMA) - Therapeutics Assessment	37
Assessment by Monotherapy Products	37
Assessment by Target	38

Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Continue.....

For more information or any query mail at sales@wiseguyreports.com

GET EXCLUSIVE DISCOUNT ON THIS REPORT @ <https://www.wiseguyreports.com/check-discount/636748-spinal-muscular-atrophy-sma-pipeline-review-h2-2016>

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

[email us here](mailto:sales@wiseguyreports.com)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.